Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/68680
Title: | MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy |
Author: | Valera Barros, Alexandra López Guillermo, Armando Cardesa Salzmann, Antonio Climent, Fina González Barca, Eva Mercadal, Santiago Espinosa, Iñigo Novelli, Silvana Briones, Javier Mate, José L. Salamero, Olga Sancho, Juan Manuel Arenillas Rocha, Leonor Serrano, Sergi Erill, Nadina Martínez, Daniel Castillo, Paola Rovira, Jordina Martínez, Antonio Campo Güerri, Elias Colomo Saperas, Lluís |
Keywords: | Limfomes Immunoteràpia Oncogens Pronòstic mèdic Lymphomas Immunotheraphy Oncogenes Prognosis |
Issue Date: | 1-Jan-2013 |
Publisher: | Ferrata Storti Foundation |
Abstract: | MYC alterations influence the survival of patients with diffuse large B-cell lymphoma. Most studies have focused on MYC translocations but there is little information regarding the impact of numerical alterations and protein expression. We analyzed the genetic alterations and protein expression of MYC, BCL2, BCL6, and MALT1 in 219 cases of diffuse large B-cell lymphoma. MYC rearrangement occurred as the sole abnormality (MYC single-hit) in 3% of cases, MYC and concurrent BCL2 and/or BCL6 rearrangements (MYC double/triple-hit) in 4%, MYC amplifications in 2% and MYC gains in 19%. MYC single-hit, MYC double/triple-hit and MYC amplifications, but not MYC gains or other gene rearrangements, were associated with unfavorable progression-free survival and overall survival. MYC protein expression, evaluated using computerized image analysis, captured the unfavorable prognosis of MYC translocations/amplifications and identified an additional subset of patients without gene alterations but with similar poor prognosis. Patients with tumors expressing both MYC/BCL2 had the worst prognosis, whereas those with double-negative tumors had the best outcome. High MYC expression was associated with shorter overall survival irrespectively of the International Prognostic Index and BCL2 expression. In conclusion, MYC protein expression identifies a subset of diffuse large B-cell lymphoma with very poor prognosis independently of gene alterations and other prognostic parameters. |
Note: | Reproducció del document publicat a: http://dx.doi.org/10.3324/haematol.2013.086173 |
It is part of: | Haematologica, 2013, vol. 98, num. 10, p. 1554-1562 |
URI: | http://hdl.handle.net/2445/68680 |
Related resource: | http://dx.doi.org/10.3324/haematol.2013.086173 |
ISSN: | 0390-6078 |
Appears in Collections: | Articles publicats en revistes (Fonaments Clínics) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
632354.pdf | 1.05 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.